Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.71 |
| ▸ | HTR2C | P28335 | 1/20 | 0.71 |
| ▸ | HTR2B | P41595 | 1/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.53 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.48 |
| ▸ | MC4R | P32245 | 1/20 | 0.47 |
| ▸ | MC5R | P33032 | 1/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 2/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11405537 | 0.94 | HTR2A (0.63) | HTR2AHTR2CHTR2BCYP1A2CYP2A6 | |
| SCHEMBL28292686 | 0.91 | HTR2A (0.57) | HTR2AHTR2CHTR2BCYP1A2CYP2A6 | |
| SCHEMBL8465868 | 0.83 | HTR2A (0.67) | HTR2AHTR2CHTR2BCYP1A2CYP2A6 | |
| SCHEMBL268036 | 0.83 | HTR2A (1.00) | HTR2AHTR2CHTR2BCYP1A2CYP2A6 | |
| SCHEMBL17413319 | 0.83 | HTR2A (1.00) | HTR2AHTR2CHTR2BCYP1A2CYP2A6 | |
| SCHEMBL31054190 | 0.83 | HTR2A (1.00) | HTR2AHTR2CHTR2BCYP1A2CYP2A6 | |
| SCHEMBL31054149 | 0.83 | HTR2A (1.00) | HTR2AHTR2CHTR2BCYP1A2CYP2A6 | |
| SCHEMBL10937919 | 0.83 | HTR2A (0.67) | HTR2AHTR2CHTR2BCYP1A2CYP2A6 | |
| SCHEMBL6301138 | 0.83 | HTR2A (0.67) | HTR2AHTR2CHTR2BCYP1A2CYP2A6 | |
| SCHEMBL6304187 | 0.83 | HTR2A (0.67) | HTR2AHTR2CHTR2BCYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119504333-A | Preparation method and application of 2-methyl-6-alkyl naphthalene | 煤炭科学技术研究院有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-114534787-B | Gas-phase dehydrogenation catalyst and method for isopentenol | 万华化学集团股份有限公司 | 2023-12-19 | — | — | CN | disclosed |
| US-20200030287-A1 | PROLINE-BASED NEUROPEPTIDE FF RECEPTOR MODULATORS | RESEARCH TRIANGLE INSTITUTE | 2020-01-30 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20100087676-A1 | ENVIRONMENTALLY BENIGN AND SIMPLIFIED METHOD FOR PREPARATION OF AROMATIC DICARBOXYLIC ACID | SAMSUNG PETROCHEMICAL CO., LTD. (KR) | 2010-04-08 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-1200076-A4 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2005-02-09 | — | — | EP | disclosed |
| EP-0757985-A1 | N-(3-PYRROLIDINYL)BENZAMIDE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1997-02-12 | — | — | EP | disclosed |
| EP-0670831-A1 | QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-09-13 | — | — | EP | disclosed |
| WO-1995009159-A1 | QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-04-06 | — | — | WO | disclosed |
| EP-0453021-A1 | Process for preparing a cycloalkanone and/or cycloalkanol | DSM N.V. (NL) | 1991-10-23 | — | — | EP | disclosed |
| EP-0425134-A1 | Condensed pyrrolo derivatives, process for their preparation and pharmaceutical compositions containing them | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1991-05-02 | — | — | EP | disclosed |
| US-4987132-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1991-01-22 | — | — | US | disclosed |
| EP-0279681-A2 | Saturated heterocyclic carboxamide derivatives | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1988-08-24 | — | — | EP | disclosed |
| US-4154715-A | Polymeric polyblend compositions toughened by addition of liquid polymers of a conjugated diene monomer | MONSANTO COMPANY (US) | 1979-05-15 | — | — | US | disclosed |
| US-4049732-A | Continuous telomerization process and its liquid products | LITHIUM CORPORATION OF AMERICA (US) | 1977-09-20 | — | — | US | disclosed |
| US-4041088-A | Recirculation telomerization process and its liquid telomers and liquid telomers produced thereby | LITHIUM CORPORATION OF AMERICA (US) | 1977-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | HTR2A 4120/4885HTR2C 2910/4885HTR2B 3791/4885 |
| US-20200030287-A1 | PROLINE-BASED NEUROPEPTIDE FF RECEPTOR MODULATORS | NPFFR1, NPFFR2, NPBWR1 | HTR2A 356/4885HTR2C 419/4885HTR2B 462/4885 |
| US-20100087676-A1 | ENVIRONMENTALLY BENIGN AND SIMPLIFIED METHOD FOR PREPARATION OF AROMATIC DICARBOXYLIC ACID | DDC, HAO2, AOC1 | HTR2A 4288/4885HTR2C 4721/4885HTR2B 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.